KR20230048517A - 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법 - Google Patents

베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230048517A
KR20230048517A KR1020237006880A KR20237006880A KR20230048517A KR 20230048517 A KR20230048517 A KR 20230048517A KR 1020237006880 A KR1020237006880 A KR 1020237006880A KR 20237006880 A KR20237006880 A KR 20237006880A KR 20230048517 A KR20230048517 A KR 20230048517A
Authority
KR
South Korea
Prior art keywords
ketotifen
nsaid
subject
administered
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237006880A
Other languages
English (en)
Korean (ko)
Inventor
재퀼린 엠. 이벌슨
토마스 에이. 달
Original Assignee
센-잼 파마슈티컬 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센-잼 파마슈티컬 엘엘씨 filed Critical 센-잼 파마슈티컬 엘엘씨
Publication of KR20230048517A publication Critical patent/KR20230048517A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237006880A 2020-08-06 2021-08-06 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법 Pending KR20230048517A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063062138P 2020-08-06 2020-08-06
US63/062,138 2020-08-06
PCT/US2021/044897 WO2022032069A1 (en) 2020-08-06 2021-08-06 Compositions and methods for treating or preventing disease associated with beta coronavirus infection

Publications (1)

Publication Number Publication Date
KR20230048517A true KR20230048517A (ko) 2023-04-11

Family

ID=80117684

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006880A Pending KR20230048517A (ko) 2020-08-06 2021-08-06 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법

Country Status (10)

Country Link
US (1) US20240033259A1 (https=)
EP (1) EP4192457B1 (https=)
JP (1) JP2023537369A (https=)
KR (1) KR20230048517A (https=)
CN (1) CN116322662A (https=)
AU (1) AU2021321535A1 (https=)
CA (1) CA3188387A1 (https=)
IL (1) IL300406A (https=)
MX (1) MX2023001570A (https=)
WO (1) WO2022032069A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046201A1 (en) 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION
CN116178373B (zh) * 2022-12-06 2024-06-18 南方科技大学 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
WO2019046201A1 (en) * 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION

Also Published As

Publication number Publication date
EP4192457A1 (en) 2023-06-14
AU2021321535A1 (en) 2023-03-23
IL300406A (en) 2023-04-01
EP4192457A4 (en) 2024-09-18
MX2023001570A (es) 2023-05-03
CN116322662A (zh) 2023-06-23
WO2022032069A1 (en) 2022-02-10
CA3188387A1 (en) 2022-02-10
JP2023537369A (ja) 2023-08-31
EP4192457B1 (en) 2026-03-25
US20240033259A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US20200323843A1 (en) Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus
JP7460772B2 (ja) コロナウイルス感染症の治療方法
JP6567781B2 (ja) ウイルス感染症の治療用チアゾリド化合物
KR20230048517A (ko) 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법
CN114699419B (zh) PLpro蛋白抑制剂在治疗或预防新型冠状病毒感染的药物中的应用
US20240115559A1 (en) Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
US10064862B2 (en) Antiviral axin stabilizer
US20230226066A1 (en) Compounds for the treatment of viral infections
CN117396505A (zh) 治疗炎症的方法
WO2017174593A1 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
US20250205268A1 (en) Treatment of viruses with antiviral nucleosides
US20230265081A1 (en) Methods of treating coronavirus
JP2025504519A (ja) Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物
JP2006514045A (ja) チプラナビル及びカプラビリンの組み合せ投与によるｈｉｖ感染症の処置
JP2023156545A (ja) コロナウイルスによる感染症治療用の医薬組成物
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240730

Comment text: Request for Examination of Application